Apollon Wealth Management LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Apollon Wealth Management LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 102.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,494 shares of the biopharmaceutical company's stock after purchasing an additional 1,772 shares during the quarter. Apollon Wealth Management LLC's holdings in Regeneron Pharmaceuticals were worth $2,216,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $32,000. Finally, Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on REGN shares. Bank of America decreased their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a report on Friday, May 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Finally, Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Trading Up 0.6%

REGN stock traded up $3.27 on Thursday, reaching $551.20. The company's stock had a trading volume of 619,467 shares, compared to its average volume of 921,032. The business has a fifty day simple moving average of $544.09 and a two-hundred day simple moving average of $617.21. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm has a market cap of $59.51 billion, a PE ratio of 14.03, a PEG ratio of 2.03 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period last year, the firm posted $9.55 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.